Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter Learning 500 Chinese characters in 30 days is possible. Abstract • About

Valvular Heart Disease

Free Subscription Articles published in Am Heart J Retrieve available abstracts of 75 articles: HTML format

Single Articles

March 2026
1. SORENSEN LM, Reinert MS, Raja AA, de Backer O, et al
   Design and rationale of the EMPagliflozin after Aortic Valve Replacement (EMPAVR) study: a randomized clinical trial.
   Am Heart J. 2026 Mar 26:107432. doi: 10.1016/j.ahj.2026.107432.
   PubMed     Abstract available
   
   
   
2. GENEREUX P, Makkar RR, Bax JJ, Pibarot P, et al
   Design and rationale of the prospective, randomized, controlled trial to assess the management of moderate aortic stenosis by clinical surveillance or transcatheter aortic valve replacement: The PROGRESS Trial.
   Am Heart J. 2026;297:107433.
   PubMed     Abstract available
   
   
   
3. PAUSCH J, Bhadra O, Weimann J, Hua X, et al
   Evolution of endoscopic mitral valve surgery over a 11-year period at a high-volume center.
   Am Heart J. 2026 Mar 17:107424. doi: 10.1016/j.ahj.2026.107424.
   PubMed     Abstract available
   
   
   
4. DIMAGLI A, Redfors B, Gaudino M
   Trial Event Rate Assumption and Noninferiority Margin in Comparative Trials of Aortic Valve Replacement.
   Am Heart J. 2026 Mar 17:107425. doi: 10.1016/j.ahj.2026.107425.
   PubMed     Abstract available
   
   
   
5. PETERSEN JK, Schops LB, Melchior S, Baker K, et al
   Admission with heart failure or atrial fibrillation before mitral valve surgery and associated outcomes.
   Am Heart J. 2026 Mar 2:107397. doi: 10.1016/j.ahj.2026.107397.
   PubMed     Abstract available
   
   
   February 2026
6. ROSSANO J, Canter C, Wolf C, Favatella N, et al
   Mavacamten in symptomatic adolescent patients with obstructive hypertrophic cardiomyopathy: design of the phase 3 SCOUT-HCM trial.
   Am Heart J. 2026;292:107283.
   PubMed     Abstract available
   
   
   January 2026
7. WANG C, Liu Z, Li Z, Yan X, et al
   STrategies for Antithrombotic tRreatment following Transcatheter Edge-to-Edge Repair in patients with severe mitral regurgitation: rationale and design of STAR-TEER trial.
   Am Heart J. 2026 Jan 28:107362. doi: 10.1016/j.ahj.2026.107362.
   PubMed     Abstract available
   
   
   
8. VEKSTEIN AM, Salah HM, Stebbins A, Wegermann Z, et al
   Early Outcomes of Off-Label Transcatheter Tricuspid Valve Repair/Replacement in the STS/ACC TVT Registry.
   Am Heart J. 2026 Jan 19:107355. doi: 10.1016/j.ahj.2026.107355.
   PubMed     Abstract available
   
   
   
9. MAYOURIAN J, Sleeper LA, Diwanji V, Geva A, et al
   Artificial intelligence-enabled electrocardiogram guidance for pulmonary valve replacement timing in repaired tetralogy of Fallot.
   Am Heart J. 2026;291:153-161.
   PubMed     Abstract available
   
   
   December 2025
10. HARVEY JE 3RD, Ryan M, Gunnarsson C, Chikermane S, et al
    Incremental cost of complications after TAVR and SAVR in contemporary clinical practice.
    Am Heart J. 2025;290:278-287.
    PubMed     Abstract available
    
    
    
11. WEI C, Sharma P, Paranjpe I, Heidenreich PA, et al
    Balancing cost and care: Analyzing commercial pricing for TAVR and SAVR.
    Am Heart J. 2025;290:1-5.
    PubMed     Abstract available
    
    
    November 2025
12. VAN DEN ENDEN AJM, van den Dorpel MMP, Mondellini GM, Mattace-Raso AM, et al
    Immediate changes in Left Ventricular Cardiac Mechanics following Transcatheter Aortic Valve Replacement for Severe Aortic Stenosis - an In-Vivo Pressure-Volume Analysis study.
    Am Heart J. 2025 Nov 13:107302. doi: 10.1016/j.ahj.2025.107302.
    PubMed     Abstract available
    
    
    
13. RAVI SN, O'Shea M, Baqal O, Fatunde OA, et al
    The incremental role of late gadolinium enhancement in risk stratifying high risk patients with hypertrophic cardiomyopathy.
    Am Heart J. 2025;289:28-37.
    PubMed     Abstract available
    
    
    
14. TOBE A, van Royen N, Amat-Santos IJ, Hudec M, et al
    Win ratio analysis of the LANDMARK trial.
    Am Heart J. 2025;289:1-5.
    PubMed     Abstract available
    
    
    October 2025
15. HEMELRIJK K, Jimenez-Diaz VA, Vilchez JP, Oteo JF, et al
    Rationale and design of REAC-TAVI 2: single antiplatelet treatment with ticagrelor versus aspirin after transcatheter aortic valve implantation.
    Am Heart J. 2025 Oct 31:107293. doi: 10.1016/j.ahj.2025.107293.
    PubMed     Abstract available
    
    
    
16. OVERDUIN DC, van Ginkel DJ, Dubois C, Lesizza P, et al
    Routine versus selective protamine administration to reduce bleeding after TAVI: Rationale and Design of the POPular ACE TAVI trial.
    Am Heart J. 2025 Oct 31:107296. doi: 10.1016/j.ahj.2025.107296.
    PubMed     Abstract available
    
    
    September 2025
17. TOMII D, Alaour B, Heg D, Okuno T, et al
    Self-Expanding Versus Balloon-Expandable Transcatheter Heart Valves in Patients with Excessive Aortic Valve Cusp Calcification.
    Am Heart J. 2025 Sep 18:S0002-8703(25)00333-3. doi: 10.1016/j.ahj.2025.
    PubMed     Abstract available
    
    
    August 2025
18. PARK HS, Suh CH, Ahn JM, Kang DY, et al
    Effect of Cerebral Embolic Protection Device on New Cerebral Embolism During Transcatheter Aortic Valve Replacement: A Prospective Sentinel Registry.
    Am Heart J. 2025 Aug 13:S0002-8703(25)00296-0. doi: 10.1016/j.ahj.2025.
    PubMed     Abstract available
    
    
    July 2025
19. JORGENSEN TH, Thyregod HGH, Blankenberg S, Leon M, et al
    The Low-Risk TAVR Trials - A Critical Appraisal of the Current Landscape.
    Am Heart J. 2025 Jul 29:S0002-8703(25)00288-1. doi: 10.1016/j.ahj.2025.
    PubMed     Abstract available
    
    
    
20. VAKILPOUR A, Levin MG, Anyanwu EC, Denduluri S, et al
    Referral patterns and clinical outcomes in patients with severe aortic stenosis: A multicenter cohort study.
    Am Heart J. 2025 Jul 22:S0002-8703(25)00223-6. doi: 10.1016/j.ahj.2025.
    PubMed     Abstract available
    
    
    
21. MOHAMMADNIA N, Vestjens LTW, Craig NJ, Tijssen JGP, et al
    The Effects of Low-Dose Colchicine on the Progression of Aortic Valve Stenosis: Rationale, Design, and Baseline Characteristics of the Colchicine and Inflammation in Aortic Stenosis (CHIANTI) trial.
    Am Heart J. 2025 Jul 12:S0002-8703(25)00219-4. doi: 10.1016/j.ahj.2025.
    PubMed     Abstract available
    
    
    June 2025
22. KRASNIQI L, Skovbo JS, Hallas PJ, Brandes PA, et al
    Impact of statin treatment on postoperative atrial fibrillation in surgical aortic valve replacement.
    Am Heart J. 2025 Jun 13:S0002-8703(25)00194-2. doi: 10.1016/j.ahj.2025.
    PubMed     Abstract available
    
    
    April 2025
23. JIANG Z, Chang S, Tao L, Luo J, et al
    The randomized controlled trial to compare temporary permanent pacemaker versus temporary pacemaker in patients with conduction block after transcatheter aortic valve replacement: rationale and design of the RECOVER trial: Randomized trial for Tempora
    Am Heart J. 2025 Apr 19:S0002-8703(25)00135-8. doi: 10.1016/j.ahj.2025.
    PubMed     Abstract available
    
    
    
24. GRBAC AJ, Lee MGY, Chye D, Zhou JY, et al
    MANAGEMENT OF ASYMPTOMATIC SEVERE AORTIC STENOSIS: A CRITICAL REVIEW OF GUIDELINES AND CLINICAL OUTCOMES.
    Am Heart J. 2025 Apr 15:S0002-8703(25)00128-0. doi: 10.1016/j.ahj.2025.
    PubMed     Abstract available
    
    
    
25. HORN N, Gartner L, Rastan AJ, Andrasi TB, et al
    Effects of a preoperative psychological expectation-focused intervention in patients undergoing valvular surgery - the randomized controlled ValvEx (valve patients' expectations) study.
    Am Heart J. 2025;282:156-169.
    PubMed     Abstract available
    
    
    February 2025
26. ANDO T, Nazif T, Briasoulis A, Afonso L, et al
    Clinical Outcomes of Direct Oral Anticoagulant Versus Warfarin After Transcatheter Aortic Valve Replacement: From the STS/ACC TVT Registry.
    Am Heart J. 2025 Feb 26:S0002-8703(25)00057-2. doi: 10.1016/j.ahj.2025.
    PubMed     Abstract available
    
    
    
27. LEENING MJG, Khan CF, Zhu F, Singh SS, et al
    Lipoprotein(a) immunoassays and their associations with coronary artery calcification and aortic valve calcification.
    Am Heart J. 2025 Feb 18:S0002-8703(25)00040-7. doi: 10.1016/j.ahj.2025.
    PubMed     Abstract available
    
    
    
28. JORGENSEN TH, Thyregod HGH, Savontaus M, Bleie O, et al
    Transcatheter or Surgical Aortic Valve Replacement in patients with Severe Aortic Stenosis Aged 70 Years or Younger - a NOTION-2 sub-study.
    Am Heart J. 2025 Feb 12:S0002-8703(25)00034-1. doi: 10.1016/j.ahj.2025.
    PubMed     Abstract available
    
    
    
29. NAKASE M, Tomii D, Maznyczka A, Heg D, et al
    Five-year outcomes with self-expanding versus balloon-expandable TAVI in patients with left ventricular systolic dysfunction.
    Am Heart J. 2025;280:18-29.
    PubMed     Abstract available
    
    
    January 2025
30. BALDI C, Maio MD, Esposito L, Bellino M, et al
    How the COAPT trial affected the selection of patients with secondary mitral regurgitation undergoing transcatheter edge-to-edge repair: insights from the GIOTTO Registry.
    Am Heart J. 2025 Jan 27:S0002-8703(25)00011-0. doi: 10.1016/j.ahj.2025.
    PubMed     Abstract available
    
    
    
31. SHECHTER A, Gupta A, Kaewkes D, Taheri H, et al
    Implications of an Off-Hours Setting in Patients Undergoing Transcatheter Edge-to-Edge Repair for Mitral Regurgitation.
    Am Heart J. 2025 Jan 2:S0002-8703(24)00341-7. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available
    
    
    December 2024
32. AARTS HM, Hemelrijk KI, Broeze GM, van Ginkel DJ, et al
    Deferral of routine percutaneous coronary intervention in patients undergoing transcatheter aortic valve implantation: rationale and design of the PRO-TAVI trial: the PRO-TAVI trial: rationale and design.
    Am Heart J. 2024 Dec 12:S0002-8703(24)00332-6. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available
    
    
    November 2024
33. REDDY KP, Shultz K, Eberly LA, Khatana SAM, et al
    Contribution margins and utilization of transcatheter aortic valve replacement versus surgical aortic valve replacement in the Medicare population.
    Am Heart J. 2024 Nov 27:S0002-8703(24)00302-8. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available
    
    
    
34. ABRAHAM B, Suppah M, Farina J, Botros M, et al
    Impact of Moderate or Severe Mitral and Tricuspid Valves Regurgitation after Transcatheter Aortic Valve Replacement.
    Am Heart J. 2024 Nov 12:S0002-8703(24)00295-3. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available
    
    
    
35. IANNOPOLLO G, Cocco M, Leone A, Sacca S, et al
    TRanscatheter Aortic-Valve Implantation with or without on-site Cardiac Surgery: the TRACS trial: TAVI in centers without on-site cardiac surgery.
    Am Heart J. 2024 Nov 4:S0002-8703(24)00281-3. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available
    
    
    October 2024
36. THURAIAIYAH J, Jorgensen TH, Jensen JM, Fuchs A, et al
    Prospective study on the impact of different anti-thrombotic therapies on subclinical leaflet thickening and its temporal dynamics in transcatheter aortic valves - The NOTION-4 trial: Anti-thrombotic therapy and TAV-HALT.
    Am Heart J. 2024 Oct 5:S0002-8703(24)00264-3. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available
    
    
    August 2024
37. SOH CH, Wright L, Baumann A, Seidel B, et al
    Use of artificial intelligence-guided echocardiography to detect cardiac dysfunction and heart valve disease in rural and remote areas: Rationale and design of the AGILE-echo trial.
    Am Heart J. 2024;277:11-19.
    PubMed     Abstract available
    
    
    
38. DISMORR M, Granbom-Koski M, Ellfors E, Ruck A, et al
    Sex differences and long-term clinical outcomes after transcatheter aortic valve replacement: a SWEDEHEART study.
    Am Heart J. 2024 Aug 9:S0002-8703(24)00185-6. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available
    
    
    
39. STAHLI BE, Linke A, Westermann D, Van Mieghem NM, et al
    A Randomized Comparison of the Treatment Sequence of Percutaneous Coronary Intervention and Transcatheter Aortic Valve Implantation: Rationale and Design of the TAVI PCI Trial.
    Am Heart J. 2024 Aug 7:S0002-8703(24)00184-4. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available
    
    
    
40. TERKELSEN CJ, Thim T, Freeman P, Dahl JS, et al
    Randomized comparison of TAVI valves: The Compare-TAVI trial.
    Am Heart J. 2024;274:84-94.
    PubMed     Abstract available
    
    
    July 2024
41. BUTT JH, Yafasova A, Thein D, Begun X, et al
    Burden of Hospitalization During the First Year Following Transcatheter and Surgical Aortic Valve Replacement.
    Am Heart J. 2024 Jul 29:S0002-8703(24)00180-7. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available
    
    
    
42. ELLFORS E, Dismorr M, Ruck A, Settergren M, et al
    Predicted prosthesis-patient mismatch and long-term clinical outcomes after transcatheter aortic valve replacement: a SWEDEHEART study.
    Am Heart J. 2024 Jul 18:S0002-8703(24)00175-3. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available
    
    
    
43. PERSITS I, Mirzai S, Sarnaik KS, Volk MC, et al
    Sarcopenia and Frailty in Patients Undergoing Transcatheter Aortic Valve Replacement.
    Am Heart J. 2024 Jul 18:S0002-8703(24)00173-X. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available
    
    
    June 2024
44. ABOU-KARAM R, Tanguturi V, Cheng F, Elmariah S, et al
    Trial Designs A44002PZS Electronic Physician Notification to Facilitate the Recognition and Management of Severe Aortic Stenosis: Rationale, design, and methods of the randomized controlled DETECT AS Trial.
    Am Heart J. 2024 Jun 29:S0002-8703(24)00163-7. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available
    
    
    
45. MIYAWAKI N, Ishizu K, Shirai S, Miyahara K, et al
    Impact of the Clinical Frailty Scale on Long-term Outcomes After Transcatheter Aortic Valve Implantation.
    Am Heart J. 2024 Jun 12:S0002-8703(24)00139-X. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available
    
    
    
46. BRUNO F, Rampone JM, Islas F, Gorla R, et al
    Echocardiographic and clinical features of patients developing prosthesis-patient mismatch after TAVR: insights from the Recovery TAVR registry.
    Am Heart J. 2024 Jun 3:S0002-8703(24)00137-6. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available
    
    
    May 2024
47. LUPU L, Haberman D, Chitturi KR, Wermers JP, et al
    Overview of 2024 FDA Advisory Panel Meeting on the TriClip Transcatheter Tricuspid Valve Repair System.
    Am Heart J. 2024 May 29:S0002-8703(24)00126-1. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available
    
    
    
48. RICHARDSON C, Gilbert T, Aslam S, Brookes CL, et al
    Rationale and design of the Early valve replacement in severe ASYmptomatic Aortic Stenosis Trial.
    Am Heart J. 2024 May 29:S0002-8703(24)00128-5. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available
    
    
    
49. GUO Y, Liu X, Li R, Ng S, et al
    Comparison of Down Sizing Strategy (HANGZHOU Solution) and Standard Annulus Sizing Strategy in type 0 bicuspid aortic stenosis patients undergoing transcatheter aortic valve replacement: Rationale and design of a randomized clinical trial.
    Am Heart J. 2024 May 1:S0002-8703(24)00098-X. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available
    
    
    April 2024
50. ETIWY M, Flannery LD, Li SX, Morrison FJ, et al
    Examining Lack of Referrals to Heart Valve Specialists as Mechanisms of Potential Underutilization of Aortic Valve Replacement.
    Am Heart J. 2024 Apr 13:S0002-8703(24)00093-0. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available
    
    
    March 2024
51. KIM M, Ahn JM, Kang DY, Kim MJ, et al
    Low- or standard-dose edoxaban versus antiplatelet therapy for leaflet thrombus and cerebral thromboembolism after TAVR: A prespecified analysis of randomized ADAPT-TAVR trial.
    Am Heart J. 2024;269:167-178.
    PubMed     Abstract available
    
    
    February 2024
52. ZHANG J, Kong XQ, Gao XF, Chen J, et al
    Transfemoral transcatheter aortic valve replacement with VitaFlow(TM) valve for pure native aortic regurgitation in patients with high surgical risk: Rationale and design of a prospective, multicenter, and randomized SEASON-AR trial.
    Am Heart J. 2024 Feb 25:S0002-8703(24)00049-8. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available
    
    
    
53. PREGOWSKI J, Pracon R, Mioduszewska A, Skowronski J, et al
    Strategy To Optimize PeriproCeduraL AnticOagulation in Structural Transseptal Interventions: Design and rationale of the STOP CLOT Trial.
    Am Heart J. 2024 Feb 22:S0002-8703(24)00043-7. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available
    
    
    
54. KEDHI E, Rroku A, Hermanides RS, Dambrink JH, et al
    TransCatheter Aortic Valve Implantation and Fractional Flow Reserve-Guided Percutaneous Coronary Intervention versus Conventional Surgical Aortic Valve Replacement and Coronary Bypass Grafting for Treatment of Patients with Aortic Valve Stenosis and M
    Am Heart J. 2024 Feb 1:S0002-8703(24)00019-X. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available
    
    
    January 2024
55. JAMMOUL N, Dupasquier V, Akodad M, Meunier PA, et al
    Long-term follow-up of balloon-expandable valves according to the implantation strategy: insight from the DIRECTAVI trial.
    Am Heart J. 2024 Jan 20:S0002-8703(24)00014-0. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available
    
    
    December 2023
56. HEGEMAN RRMJJ, van Ginkel DJ, Langle S, Timmers L, et al
    Preoperative CT-imaging with patient-specific computer simulation in transcatheter aortic valve implantation: Design and rationale of the GUIDE-TAVI trial.
    Am Heart J. 2023 Dec 30:S0002-8703(23)00360-5. doi: 10.1016/j.ahj.2023.
    PubMed     Abstract available
    
    
    
57. GENEREUX P, Schwartz A, Oldemeyer B, Cohen DJ, et al
    Design and Rationale of the Evaluation of Transcatheter Aortic Valve Replacement Compared to SurveilLance for Patients with AsYmptomatic Severe Aortic Stenosis: The EARLY TAVR Trial.
    Am Heart J. 2023 Dec 4:S0002-8703(23)00326-5. doi: 10.1016/j.ahj.2023.
    PubMed     Abstract available
    
    
    
58. SEVERINSEN T, Thune JJ, Gudmundsdottir HL, Vissing CR, et al
    Angiotensin receptor blockers in patients with hypertrophic cardiomyopathy: A comparison of VANISH and INHERIT randomized trials.
    Am Heart J. 2023;266:198-200.
    PubMed     Abstract available
    
    
    November 2023
59. KIM M, Choi JH, Kim HK, Kim HL, et al
    Effects of Intensive Blood Pressure Control on Left Ventricular Hypertrophy in Aortic Valve Disease.
    Am Heart J. 2023 Nov 23:S0002-8703(23)00321-6. doi: 10.1016/j.ahj.2023.
    PubMed     Abstract available
    
    
    
60. STRANGE JE, Nouhravesh N, Schou M, Christensen DM, et al
    High-risk admission prior to transcatheter aortic valve replacement and subsequent outcomes: Preceding events and outcomes after TAVR.
    Am Heart J. 2023 Nov 14:S0002-8703(23)00311-3. doi: 10.1016/j.ahj.2023.
    PubMed     Abstract available
    
    
    October 2023
61. BARON SJ, Ryan MP, Chikermane SG, Thompson C, et al
    Long-Term Risk of Reintervention after Transcatheter Aortic Valve Replacement.
    Am Heart J. 2023 Oct 21:S0002-8703(23)00296-X. doi: 10.1016/j.ahj.2023.
    PubMed     Abstract available
    
    
    August 2023
62. DODGSON CAS, Beitnes JO, Klove SF, Herstad J, et al
    An investigator-sponsored pragmatic randomised controlled trial of AntiCoagulation versus AcetylSalicylic Acid after Transcatheter Aortic Valve Implantation - Rationale and design of ACASA-TAVI: Blinded outcome adjudication.
    Am Heart J. 2023 Aug 25:S0002-8703(23)00208-9. doi: 10.1016/j.ahj.2023.
    PubMed     Abstract available
    
    
    
63. L'HOYES W, Robyns T, Moura-Fereira S, De Meester P, et al
    Effectiveness of the Risk Stratification Proposed by the 2022 European Heart Rhythm Association Expert Consensus Statement on Arrhythmic Mitral Valve Prolapse.
    Am Heart J. 2023 Aug 16:S0002-8703(23)00201-6. doi: 10.1016/j.ahj.2023.
    PubMed     Abstract available
    
    
    
64. SOLOMON MD, Tabada G, Sung SH, Allen A, et al
    Physician Assessment of Aortic Stenosis Severity, Quantitative Parameters, and Long-Term Outcomes: Results from the KP-VALVE Project.
    Am Heart J. 2023 Aug 6:S0002-8703(23)00182-5. doi: 10.1016/j.ahj.2023.
    PubMed     Abstract available
    
    
    July 2023
65. KALMUCKI P, Lipiecki J, Witte KK, Goldberg SL, et al
    Percutaneous mitral annuloplasty with the Carillon device: outcomes in proportionate and disproportionate functional mitral regurgitation.
    Am Heart J. 2023 Jul 27:S0002-8703(23)00181-3. doi: 10.1016/j.ahj.2023.
    PubMed     Abstract available
    
    
    June 2023
66. SEGUCHI M, Aytekin A, Steiger L, Nicol P, et al
    Near-infrared Spectroscopy-Intravascular Ultrasound to Improve Assessment of Coronary Artery Disease Severity in Patients Referred for Transcatheter Aortic Valve Implantation (The IMPACTavi registry): Design and Rationale.
    Am Heart J. 2023 Jun 12:S0002-8703(23)00159-X. doi: 10.1016/j.ahj.2023.
    PubMed     Abstract available
    
    
    
67. KIRMANI S, Woodard PK, Shi L, Hamza TH, et al
    Cardiac Imaging and Biomarkers for Assessing Myocardial Fibrosis in Children with Hypertrophic Cardiomyopathy.
    Am Heart J. 2023 Jun 12:S0002-8703(23)00160-6. doi: 10.1016/j.ahj.2023.
    PubMed     Abstract available
    
    
    
68. SHECHTER A, Koren O, Skaf S, Makar M, et al
    Transcatheter Edge-to-Edge Repair for Chronic Functional Mitral Regurgitation in Patients with Very Severe Left Ventricular Dysfunction.
    Am Heart J. 2023 Jun 3:S0002-8703(23)00138-2. doi: 10.1016/j.ahj.2023.
    PubMed     Abstract available
    
    
    
69. MEWTON N, Donal E, Picard F, Derimay F, et al
    Prognostic impact of precipitated cardiac decompensation in symptomatic heart failure with reduced ejection fraction and severe secondary mitral regurgitation.
    Am Heart J. 2023 Jun 2:S0002-8703(23)00137-0. doi: 10.1016/j.ahj.2023.
    PubMed     Abstract available
    
    
    
70. RYMER JA, Sun JL, Chiswell K, Cohen D, et al
    Variation in resource utilization and mortality among patients with varying MR type and severity.
    Am Heart J. 2023;260:44-57.
    PubMed     Abstract available
    
    
    May 2023
71. BEGUN X, Butt JH, Kristensen SL, Weeke PE, et al
    Patient Characteristics and Long-term Outcomes in Patients Undergoing Transcatheter Aortic Valve Implantation in a Failed Surgical Prosthesis versus in a Native Valve: A Danish nationwide study.
    Am Heart J. 2023 May 11:S0002-8703(23)00118-7. doi: 10.1016/j.ahj.2023.
    PubMed     Abstract available
    
    
    April 2023
72. LAURIDSEN MD, Valentin JB, Strange JE, Jacobsen PA, et al
    Mortality in patients with chronic obstructive pulmonary disorder undergoing transcatheter aortic valve replacement: The importance of chronic obstructive pulmonary disease exacerbation.
    Am Heart J. 2023;262:100-109.
    PubMed     Abstract available
    
    
    
73. COISNE A, Aghezzaf S, Butruille L, Woitrain E, et al
    Incidence, Source, and Prognostic Impact of Major Bleeding Across the Spectrum of Aortic Stenosis.
    Am Heart J. 2023 Apr 24:S0002-8703(23)00099-6. doi: 10.1016/j.ahj.2023.
    PubMed     Abstract available
    
    
    
74. DEMIREL C, Tomii D, Heg D, Okuno T, et al
    Incidental detection of malignancy during pre-procedural workup for transcatheter aortic valve implantation: a longitudinal cohort study.
    Am Heart J. 2023 Apr 1:S0002-8703(23)00072-8. doi: 10.1016/j.ahj.2023.
    PubMed     Abstract available
    
    
    October 2021
75. ANANTHAKRISHNA R, Lee SL, Foote J, Sallustio BC, et al
    Randomized controlled trial of perhexiline on regression of left ventricular hypertrophy in patients with symptomatic hypertrophic cardiomyopathy (RESOLVE-HCM trial).
    Am Heart J. 2021;240:101-113.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Valvular Heart Disease is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum